GLP-1 analogue, reference only
Tirzepatide
Dual GIP/GLP-1 co-agonist with biased GIPR activity; once-weekly SC dosing via C20-diacid albumin binding.
Tirzepatide is not in our range right now. This page documents it from the literature for research reference only, not for human use. Compounds available to order are listed below.
Specification
- Molecular weight
- 4,813.53 Da
- Half-life
- 5 d
- Research area
- GLP-1 analogue
Also called Mounjaro, Zepbound, LY3298176
~5 days (~117 h) in humans SC. Two-compartment PK; 99% albumin-bound via C20 fatty-diacid linker at Lys20. Schneck et al., CPT: Pharmacometrics 2024; Mounjaro FDA label.
About the research
Tirzepatide (LY3298176) is Eli Lilly's first-in-class dual incretin agonist, combining GIP and GLP-1 receptor activation in a single 39-amino-acid scaffold. Its imbalanced pharmacology — full GIPR activity with attenuated GLP-1R signaling — produced unprecedented weight-loss magnitudes in SURMOUNT trials, making it the leading benchmark for current and next-generation polyagonist research.
Mechanism, reported research areas, literature dose ranges and co-factor studies are on the research page, with sources. Nothing there is a claim about this product.
Read the Tirzepatide research overview- Glycemic control studies in T2D models (HbA1c, insulin sensitivity)
- Adiposity and lean-mass partitioning in DIO rodents
- Hepatic steatosis (MASH/NASH) preclinical research
- Comparator arm vs. mono-GLP-1 agonists
- Reported research areas, from the literature. Not product claims.
In stock now
All products
Wolverine Blend€119.90Repair
